NCT05491525ClinicalTrials.gov
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)
En bref
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
Phase 2 / Phase 371 participants recherchés38 sites16 pays
Catégories
Enregistré dans 1 registre
- ClinicalTrials.govNCT05491525Ouvrir cette fiche sur ClinicalTrials.govSynchronisé il y a 2 mois
Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.
Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.
Cette étude vous intéresse ?
Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2022-08-08; recorded start 2022-10-12
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Urovant Sciences GmbH)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Non-randomised allocation
- Blinding0/20
Open-label
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 38 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A small study, international in scope: 71 participants (target), run at 38 sites, across 16 countries.
How this score is built
- Enrolment17/40
71 participants (target)
- Site count19/25
38 sites
- Country count15/15
16 countries
- Planned duration10/10
Planned over about 96 months
- Sponsor scale0/10
Urovant Sciences GmbH has led 1 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Résumé
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
Affections
- Neurogenic Detrusor Overactivity
Éligibilité
| Sexe | Tous |
|---|---|
| Âges | 2 Years – 17 Years |
| Volontaires sains | Non |
Éligibilité telle qu'elle figure dans le registre
Éligibilité en énoncés simples
Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.
Conception de l'étude
| Type d'étude | Interventionnelle |
|---|---|
| Phase | Phase 2 / Phase 3 |
| Répartition | Non randomisée |
| Modèle d'intervention | PARALLEL |
| Objectif principal | TREATMENT |
| Insu | NONE (0) |
| Recrutement | 71 participants recherchés |
Promoteur et collaborateurs
- Urovant Sciences GmbH Promoteur
- Sumitomo Pharma America, Inc. Collaborateurs
Groupes et interventions
- Cohort 1: Weight >=41.5kgEXPERIMENTAL
Part A: Participants will receive a dose of Vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times. Part B: Participants will receive a Data and Safety Monitoring Board (DSMB)-selected Vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A.
- Cohort 2: Weight Range >=29.5 kg to <=41.4 kgEXPERIMENTAL
Part A: participants will receive a dose of Vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times. Part B: Participants will receive a DSMB-selected Vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A.
- Cohort 3: Weight range >=11 kg to <=29.4 kgEXPERIMENTAL
Part A: Participants will receive a dose of Vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times. Part B: Participants will receive a DSMB-selected Vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A.
Interventions
- Médicament Vibegron
Participants will be administered Vibegron orally, once daily (QD)
Critères de jugement
Critère de jugement principal
Change from Baseline in maximum cystometric capacity (MCC) based on bladder filling urodynamics
Délai Optimized Treatment Week 24
Critère de jugement secondaire
Change from Baseline in MCC
Délai Optimized Week 12
Critère de jugement secondaire
Change from Baseline in number of overactive detrusor contractions until the end of bladder filling
Délai Optimized Treatment Weeks 12 and 24
Critère de jugement secondaire
Change from Baseline in detrusor pressure at the end of bladder filling
Délai Optimized Treatment Weeks 12 and 24
Critère de jugement secondaire
Change from Baseline in bladder filling volume until first involuntary/hyperactive detrusor contraction
Délai Optimized Treatment Weeks 12 and 24
Critère de jugement secondaire
Change from Baseline in bladder compliance (mL/cm H2O)
Bladder compliance is calculated by dividing the change in volume by the change in detrusor pressure during the filling of the bladder
Délai Optimized Treatment Weeks 12 and 24
Critère de jugement secondaire
Change from Baseline in average first morning catheterized volume
Délai through study completion, an average of 52 weeks
Critère de jugement secondaire
Change from Baseline in average catheterized volume per catheterization
Délai through study completion, an average of 52 weeks
Critère de jugement secondaire
Change from Baseline in average maximum catheterized volume per day
Délai through study completion, an average of 52 weeks
Critère de jugement secondaire
Change from Baseline in average maximum catheterized daytime volume
Délai through study completion, an average of 52 weeks
Critère de jugement secondaire
Change from Baseline in average number of leakage episodes per day
Délai through study completion, an average of 52 weeks
Critère de jugement secondaire
Change from Baseline in estimated number of dry (leakage-free) days/ 7 days
Délai through study completion, an average of 52 weeks
Critère de jugement secondaire
Change from Baseline in Pediatric Incontinence Questionnaire (PIN-Q)
PIN-Q is a 20-item questionnaire addressing quality of life for participants with bladder disorders. Each question was answered on a scale from 0 (no, never) to 4 (all the time). The total score ranged from 0 to 80, with higher scores indicating more impact on the quality of life.
Délai through study completion, an average of 52 weeks
Critère de jugement secondaire
Change from Baseline in Patient Global Impression of Severity (PGI-S) Scale
PGI-S is a 5 point scale that determines the bladder condition of a participant with 0 being really bad and 4 as really good. Higher score indicates better bladder condition.
Délai through study completion, an average of 52 weeks
Critère de jugement secondaire
Change from Baseline in Clinical Global Impression of Change (CGI-C) Scale
The CGI-C scale is used to determine the degree of change in participant's overall bladder symptoms since the start of the study on Day 1. The scale will be filled by the investigator by ticking on any of the following options: very much improved, much improved, minimally improved, no change, minimally worse, much worse and very much worse.
Délai through study completion, an average of 52 weeks
Dates
| Date de début | 12 octobre 2022 (réelle) |
|---|---|
| Achèvement principal | 1 mars 2030 (estimée) |
| Achèvement | 1 septembre 2030 (estimée) |
| Première publication | 8 août 2022 (réelle) |
| Dernière mise à jour | 15 juin 2026 |
| Résultats publiés | Non précisé dans la fiche du registre |
| Statut vérifié pour la dernière fois | juin 2026 |
Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.
Lieux
32 sites sont en recrutement
Belgium
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Universitair Ziekenhuis Antwerpen | Edegem | Antwerpen | Retiré |
| UZ Gent | Ghent | East Flanders | En recrutement |
Canada
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Alberta Children's Hospital | Calgary | Alberta | En recrutement |
| The Hospital for Sick Children | Toronto | Ontario | En recrutement |
Croatia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| University Hospital Split - KBC Split | Split | En recrutement |
Denmark
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Aarhus University Hospital - Department of Paediatrics and Adolescent Medicine | Aarhus | En recrutement |
Georgia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| JSC Evex Hospital M. lashvili Childrens Central Hospital | Tbilisi | En recrutement |
Jordan
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Jordan University Hospital | Amman | En recrutement | |
| Istiklal Hospital | Amman | En recrutement | |
| Irbid Specialty Hospital | Irbid | En recrutement |
Latvia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Childrens Clinical University Hospital | Riga | Retiré |
Lithuania
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Hospital of Lithuanian University of Health Sciences Kauno klinikos | Kaunas | En recrutement | |
| Vilnius University Hospital Santaros Klinikos | Vilnius | En recrutement |
Malaysia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Kuala Lumpur Hospital | Kuala Lumpur | Kuala Lumpur | En recrutement |
| Hospital Umum Sarawak | Kuching | Sarawak | En recrutement |
Philippines
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| National Children's Hospital | Quezon City | National Capital Region | En recrutement |
Poland
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa | Bialystok | En recrutement | |
| Uniwersyteckie Centrum Kliniczne | Gdansk | En recrutement | |
| Instytut Pomnik - Centrum Zdrowia Dziecka | Warsaw | En recrutement |
Romania
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Institutul Clinic Fundeni | Bucharest | Bucharest | En recrutement |
| Maria Sklodowska Curie Childrens Clinical Emergency Hospital | Bucharest | Bucharest | En recrutement |
Serbia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| University Children's Hospital Tirsova | Belgrade | En recrutement | |
| Children and Youth Health Care Institute of Vojvodina | Novi Sad | En recrutement |
Slovakia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Detská fakultná nemocnica s poliklinikou/Národný ústav detských chorôb (NÚDCH) | Bratislava | En recrutement | |
| Urologická ambulancia J. BREZA MEDICAL s.r.o. | Bratislava | En recrutement |
Turkey (Türkiye)
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Ankara University Faculty of Medicine Ibni Sina Hospital | Ankara | Altindag | En recrutement |
| Mersin University, Dept. of Urology | Yenişehir | En recrutement |
United States
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Albany Medical College | Albany | New York | En recrutement |
| Children's Hospital Colorado | Aurora | Colorado | En recrutement |
| Duke University Medical Center | Durham | North Carolina | Arrêté prématurément |
| Nemours Childrens Health, Jacksonville | Jacksonville | Florida | En recrutement |
| Arkansas Childrens Hospital | Little Rock | Arkansas | En recrutement |
| Childrens Hospital New Orleans | New Orleans | Louisiana | Retiré |
| University of Oklahoma | Oklahoma City | Oklahoma | En recrutement |
| Children's Hospital of Orange County | Orange | California | Arrêté prématurément |
| Oregon Health & Science University | Portland | Oregon | Retiré |
| SUNY Upstate Medical University | Syracuse | New York | En recrutement |
| Wichita Urology Group | Wichita | Kansas | En recrutement |
Documents de l'étude
Aucun document n'est lié dans cette fiche du registre.
Évolution au fil du temps
Aucun changement n'a été enregistré depuis que nous avons intégré cette fiche pour la première fois.
Un changement est enregistré chaque fois que le promoteur met à jour la fiche du registre. Le statut, les dates, le recrutement et les sites apparaissent ici au fur et à mesure de leur évolution.